ABSTRACT
-bradykinin from rabbit or human recombinant B 1 receptors expressed in human embryonic kidney (HEK) 293 cells and is a surmountable antagonist in the rabbit aorta contractility assay (pA 2 , 7.49). B-10378 was a full agonist at the naturally expressed B 1 receptor (rabbit aorta contraction, calcium transients in human smooth muscle cells) and had a binding competition K i of 19 or 89 nM at the recombinant rabbit or human receptor, respectively. Both fluorescent probes can label with specificity human or rabbit B 1 receptors expressed in HEK 293 cells (epifluorescence or confocal microscopy), but the agonist was associated with discontinuous plasma membrane labeling, which coincided with that of a red-emitting caveolin-1 conjugate. Cytofluorometry with B-10376 was applied to recombinant and, in human vascular smooth muscle cells, to naturally expressed B 1 receptors. In all fluorescent applications, the specific labeling was reduced by an excess of a B 1 receptor nonpeptide antagonist. Despite the loss of affinity determined by the introduction of a fluorophore in B 1 receptor agonist or antagonist peptides, the resulting agents allow original applications (imaging in live cells, cytofluorometry).
The bradykinin B 1 receptor is a widely used nomenclature that is somewhat misleading because bradykinin has negligible affinity for this receptor type that is rather responsive to des-arginine 9 -bradykinin (des-Arg 9 -BK) and Lys-desArg 9 -BK (Leeb-Lundberg et al., 2005) . This G protein-coupled receptor has two properties of interest: the vigorous regulation of its expression and an original adaptation mechanism to agonist stimulation. First, unlike the widely distributed and preformed B 2 receptors, the expression of B 1 receptors is induced under inflammatory or tissue injury conditions (e.g., in injured or ischemic vascular cells in vivo, in circulating peripheral T cells during multiple sclerosis flares, in cultured cells of various types stimulated with inflammatory cytokines; Agata et al., 2000; Emanueli et al., 2002; Prat et al., 2005; Moreau et al., 2007; Bawolak et al., 2008b) . Current evidence indicates that this G protein-coupled receptor is not submitted to agonist-induced phosphorylation or internalization, contrary to the related bradykinin B 2 receptor (Leeb-Lundberg et al., 2005) . However, Sabourin et al. (2002) have observed a special form of agonist-induced translocation using a fusion protein composed of the rabbit B 1 receptor conjugated to the yellow fluorescent protein (B 1 R-YFP): the smooth membrane distribution of the receptor-associated fluorescence evolved toward condensed structures that remained associated with the plasma membrane. This translocation was inhibited by pharmacological antagonists of the B 1 receptors, showing that this response is dependent on a form of signaling, and also by cell pretreatment with ␤-cyclodextrin, supporting that the structures where B 1 R-YFP concentrate are a variety of cholesterol-rich rafts (Sabourin et al., 2002; Morissette et al., 2004) . Furthermore, unlike the stable B 2 receptors, the B 1 receptors are apparently short-lived at the cell surface, where they are cleared in a ligand-independent manner (Fortin et al., 2003) .
A complementary manner to approach both the cell surface expression and the subcellular translocation of the kinin B 1 receptor translocation could be to exploit fluorescent ligands. We took advantage from the tolerance of this receptor type for N-terminal extension of the peptide ligands, as shown by the development of the high-affinity radioligand 125 I-TyrGly-Lys-ε-aminocaproyl-Lys-des-Arg 9 -BK (Levesque et al., 1995) or of the highly potent antagonist B-10324 (Gera et al., 2008) , to introduce a fluorescein fluorophore, with or without a spacer, at the N terminus of the agonist Lys-des-Arg 9 -BK or of the high-affinity antagonist B-9958 (Gera et al., 1996) . These new tools were pharmacologically characterized at the rabbit and human B 1 receptors and label recombinant receptors from these species (epifluorescence). Furthermore, two types of application were illustrated for these ligands because they were exploited to experimentally address agonistinduced lateral translocation of the B 1 receptors at the plasma membrane and their cell surface expression in cultured cells using cytofluorometry. We recently have reported elsewhere a similarly designed fluorescent derivative of the bradykinin B 2 receptor antagonist, B-9430 (Bawolak et al., 2008a) . Table 1 ) were synthesized, purified, and characterized using general methods described elsewhere (Gera et al., 1996) . Compound 11 is a powerful nonpeptide antagonist at the human and rabbit B 1 receptors (Morissette et al., 2004) receptor extended with a C-terminal FLAG epitope and for the wildtype rabbit B 1 receptor has been described previously (Larrivée et al., 2000; Morissette et al., 2008) . The empty FLAG vector (without a start codon, gift from Dr. Patrick Provost, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada) was used in some control experiments. A subclone of HEK 293 cells (dubbed HEK 293a) was obtained from Sigma-Aldrich. These cells were grown and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics. Expression vectors were transiently transfected for 24 h with the use of the EX-Gen 500 transfection reagent (MBI Fermentas, Hanover, MD) as directed.
Materials and Methods

Drugs and
The vector caveolin-1-GFP has been described previously (Pelkmans et al., 2001 ) and obtained from Dr. A. Helenius. The canine caveolin-1 coding sequence has been excised and inserted at the same position into a vector coding for cherry fluorescent protein to obtain a red-emitting fusion protein.
10 -kallidin; 69 -88 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). The binding assays were performed using intact, adherent HEK 293a cells (24-well plates) at physiologic ionic strength. The cells were washed twice with the binding medium and filled with 0.5 ml of prewarmed (37°C) binding medium. The binding medium was serum-free culture Medium 199 (Invitrogen) supplemented with 0.1% bovine serum albumin and sodium azide [0.02% (w/v)] for the peptide radioligand of the B 1 receptor only; 1 M amastatin, 1 M captopril, and 1 M phosphoramidon (Sigma-Aldrich) were added to the binding medium (as in our previous reports; Sabourin et al., 2002; Moreau et al., 2007) . The experiments dealt with the effect of cell coincubation of the radioligand at a fixed concentration (1 nM) with a panel of unlabeled drugs. After 60 min of incubation at 37°C, each well was washed three times with 1 ml (2 ml for vascular cells) of ice-cold phosphatebuffered saline, pH 7.4. One milliliter of 0.1 M NaOH was finally added to dissolve the cells. Radioactivity in the resulting suspension was determined by scintillation counting (2-5 min/vial). Data were fitted by nonlinear regression to a one-site competition equation to derive EC 50 values (Prism 4.0; GraphPad Software Inc., San Diego, CA), from which K i values were calculated using the Cheng and Prusoff (1973) method.
Contractility Assay: Rabbit Aorta. A local animal care committee approved the procedures based on rabbits. Rabbit aortic rings were suspended under a tension of 2 g in 5-ml tissue baths containing oxygenated (95% O 2 :5% CO 2 ) and warmed (37°C) Krebs' solution (Fortin et al., 2005a) . The procedure described in the latter report was applied precisely to measure the potency of novel fluorescent peptide antagonists against the B 1 receptor agonist des-Arg 9 -BK. The concentration-response curves for the contraction induced by this agonist were constructed 5.5 h from tissue mounting. Other tissues were used to construct cumulative concentration-response curves for the novel agonist B-10378, which was compared with the natural sequences des-Arg 9 -BK and Lys-des-Arg 9 -BK. The concentration-effect data were analyzed with Prism 4.0. The parameters of the Schild regression (pA 2 value, slope) were calculated using the software Pharm/PCS (Tallarida and Murray, 1987) , with replicated concentration ratio values for each antagonist concentration derived from paired control tissues from the same animal.
Calcium Mobilization. The institutional research ethics board approved the anonymous use of human umbilical cord segments obtained after elective cesarean section deliveries. Primary cultures of human umbilical artery smooth muscle cells, which express endogenous kinin B 1 receptors (Morissette et al., 2006; Moreau et al., 2007) , were obtained and propagated as described. To quantify the calcium mobilization induced or influenced by several B 1 receptor ligands in naturally expressed receptors of human origin, Fura-2 fluorometry (Invitrogen, Carlsbad, CA) was applied to the smooth muscle cells maintained in serum-containing medium, detached using trypsin-ethylenediamine tetraacetic acid, suspended in complete culture medium containing fetal bovine serum (to neutralize the trypsin), counted, centrifuged for 5 min at 1100 rpm at room temperature, and resuspended in Hanks' balanced salt solution (1ϫ, pH 7.4, prepared from 10ϫ concentrate; Wisent Canadian Laboratories, St. Bruno, QC, Canada) with 10 mM HEPES and 1.6 mM CaCl 2 . At this point, Fura-2-acetoxymethyl ester was added to cell suspensions (final concentration, 1 M) and incubated for 30 min in a 37°C bath with agitation. After the incubation, cells were centrifuged and rinsed twice. Calcium mobilization was read with a thermostated (37°C) spectrofluorometer (FluoroLog-3; Horiba Jobin Yvon, Edison, NJ; excitation, 340 nm; emission, 510 nm) in a 2-ml suspension of cells loaded with Fura-2 (2.5 ϫ 10 6 cells/ml), with optional drug pretreatments 50 s before stimulations. After the readings, the maximal mean fluorescence (F max ) was measured by adding ionomycin (5 M) and the minimal mean fluorescence (F min ) was measured by adding MnCl 2 (25 mM). Calcium mobilization concentrations were established with the following equation:
, where y represents the fluorescence reading from the sample, as described by Burelout et al. (2004) .
Microscopy. HEK 293a cells expressing or not a receptor-coding vector (24-h transient transfection) were treated for 30 min with a fluorescent peptide, added to the serum-containing culture medium, and optionally pretreated with another nonfluorescent B 1 receptor ligand, the antagonist compound 11 (applied 60 s before the fluorescent peptides). The cells were incubated at 37°C, rinsed three times with phosphate-buffered saline, observed (400ϫ, both phase contrast and epifluorescence with blue excitation and green emission filters), and photographed. Confocal sections of cells grown on a poly-Llysine-coated glass surface were also taken using a Volocity spinning 
NJ).
Cytofluorometry. To evaluate the potential of one of the fluorescent B 1 receptor ligands, B-10376, to yield quantitative information on the expression of receptors levels, cytofluorometry was applied to HEK 293a cells transiently expressing rabbit recombinant receptors. Some transfected cells were pretreated with the protein synthesis inhibitor, anisomycin (10 M), 2 or 4 h before staining to evidence the spontaneous decay of the cell surface B 1 receptors in the absence of its replacement by newly formed proteins (Fortin et al., 2003) . The cells were detached using the protease-free Cell Dissociation Buffer (Invitrogen), incubated in Dulbecco's modified Eagle's medium without serum at 37°C for 30 min under agitation in the presence of B-10376 (100 nM), compound 11 (1 M), their combination, or no ligand, rapidly centrifuged (30 s, 15,000g), and resuspended in phosphate-buffered saline. Then, cell suspensions were analyzed using the EPICS XL cytofluorometry apparatus (Beckman Coulter, Fullerton, CA; green fluorescence); results were analyzed using the System II software (version 3.0; Beckman Coulter). Cytofluorometry was also applied to human umbilical artery smooth muscle cells were cultured as described and stimulated with interleukin-1␤ (5 ng/ml; R&D Systems, Minneapolis, MN) for an additional 4-h period without serum starvation (Moreau et al., 2007) . The cells were detached using trypsin-ethylenediamine tetraacetic acid, incubated in Medium 199 without serum at 37°C for 30 min under agitation, and the staining and analysis were performed as outlined above.
Results
Radioligand Binding Competition Assay. The displacement of [
3 H]Lys-des-Arg 9 -BK (1 nM) from the human B 1 R-FLAG or rabbit wild-type B 1 receptor constructions transiently expressed in HEK 293a cells was used to evaluate the affinities of the fluorescent derivatives at the human form of the B 1 receptor (Fig. 1) . The reference agonist (Lys-des-Arg 9 -BK) and antagonist (B-9958) were very potent to displace the radioligand (nanomolar K i values reported in Table 2 ), but their fluorescent derivatives were much less potent, supporting that the fluorophore, with or without the ε-aminocaproyl spacer, has a detrimental effect on receptor affinity (peptide structure in Table 1 ). Thus, the antagonists B-10372 and B-10376, which exhibited very similar potencies at receptors from each species, were 5-to 6-fold less potent than B-9958 at the rabbit B 1 receptor but ϳ32-fold less potent than the parent peptide at the human receptor. The agonist B-10378 was ϳ24-fold less potent than Lys-des-Arg 9 -BK at the rabbit receptor but ϳ200-fold less potent at the human B 1 receptor ( Fig. 1; Table 2 ).
Organ Bath Pharmacology: Functional Assessment of Novel Fluorescent Ligands at the Naturally Expressed Rabbit B 1 Receptors. Rabbit aortic rings preincubated in vitro exhibit a contractile response to kinins exclusively mediated by B 1 receptors. This preparation is suitable to characterize both agonists and antagonists of this receptor type. The fluorescent derivatives of the antagonist B-9958, B-10372 and B-10376, have no direct stimulant effect on the vascular smooth muscle and competitively antagonize the conventional agonist des-Arg 9 -BK with a similar potency (pA 2 estimated at 7.59 and 7.49 from the Schild plots, respectively) ( Fig. 2E ; Table 2 ). The slopes of Schild regression was close to unity in both cases. The parent peptide, B-9958, is surmountable as well in this preparation but also more potent (pA 2 8.27, up to 9.11 in the presence of the aminopeptidase inhibitor amastatin; Gera et al., 2006) . B-10378 is a full agonist ϳ3-fold less potent than its parent peptide, Lys-des-Arg 9 -BK, but ϳ2.5-fold more potent than des-Arg 9 -BK (Fig. 2F) , showing that the N-terminal extension used to introduce the fluorophore offsets only partially the gain of affinity conferred by the Lys 0 residue at the rabbit B 1 receptor (Table 1) . In contractility experiments, the experimental Hill slope of the des-Arg 9 -BK concentration-effect curve (1.27, Table 2 ) is similar to that of B-10378 (1.18), but that of Lys-des-Arg 9 -BK was inferior (0.84). This is possibly related to the fact that the latter peptide, as opposed to des-Arg 9 -BK or ligands protected at their N terminus, is susceptible to aminopeptidase N degradation in the aorta (Fortin et al., 2005a) .
Calcium Transients: Functional Assessment of Novel Fluorescent Ligands at the Naturally Expressed Human B 1 Receptors. The effects of the fluorescent peptides were verified at the endogenously expressed B 1 receptors of the human umbilical artery smooth muscle cells using a calcium mobilization assay (Fig. 3) . B-10378 (1 M) acutely reproduced the stimulant effect of the natural agonist Lysdes-Arg 9 -BK (10 nM), whereas the antagonist-derived agents B-10372 and B-10376 were not active in this respect at 100 nM ( Fig. 3A ; the chosen concentration levels of all agents were effective to displace the radioligand binding from the human B 1 receptors, Fig. 1, A and B) . However, at 1 M, B-10372 and B-10376 prevented the effect of the natural agonist (10 nM; Fig. 3B ). Thus, these experiments confirm the pharmacological identity of the three novel carboxyfluorescein-conjugated ligands at the human B 1 receptor (B-10378 is an agonist, and the others are antagonists).
Imaging of B 1 Receptors Expressed in HEK 293a Cells. Cells that transiently expressed recombinant B 1 receptors were treated in their regular culture medium with a uniform concentration of fluorescent peptides (50 nM), incubated for 30 min at 37°C, rinsed, and observed in epifluorescence microscopy. The antagonists B-10372 or B-10376 labeled the plasma membrane surface in cells that expressed the human B 1 R-FLAG or rabbit wild-type B 1 receptor (Fig.  4) . As expected from transient transfection, the labeling intensity varied widely, with some cells not labeled. Staining by fluorescent antagonists was not conferred by the empty FLAG vector and was greatly reduced by cotreating receptorexpressing cells with the high-affinity nonpeptide antagonist, compound 11 (Fig. 4) (Morissette et al., 2004) . The B 1 receptor agonist B-10378 also labeled cells that expressed recombinant B 1 R-FLAG or rabbit B 1 receptors (50 nM, 30-min treatment, Fig. 5) , and control experiments also showed negligible cell fluorescence in the presence of compound 11 and in the absence of the receptors or of the fluorescent agonist. The fading of the specific fluorescent signal under blue light excitation was significant for both fluoresceinlabeled antagonists and the agonist.
The antagonist version of the fluorescent ligand, B-10376, still labeled many cells transfected with either B 1 receptor construction when its concentration was reduced as low as 5 to 10 nM (Fig. 6 ), congruent with its K i values at these receptors (Table 2 ). In comparison, the agonist B-10378 was less potent to label cells observed in epifluorescence, especially those expressing the human receptor (Fig. 6 ), a fact that may be explained in part by the low affinity of this probe for the human receptor (Table 2) microscopic planes to study the qualitative difference of labeling pattern between the agonist B-10378 and the antagonist B-10376 (Fig. 7) . Although nontransfected cells showed minimal peptide binding, B 1 receptor-expressing cells were labeled with either peptide with intensities higher than the autofluorescence or that of treated but nontransfected cells that expressed no receptor. In receptor-expressing cells observed near the equatorial plane, the plasma membrane was labeled with continuity (white arrowheads) by B-10376 (20 nM) in 58.6% of positive cells for the rabbit receptors and 34.0% of the cells expressing the human receptors. The proportion of continuous labeling was significantly lower ( 2 test) for cells expressing the B 1 receptor of each species and labeled with the agonist form B-10378 (20 nM) (Fig. 7 , bottom); instead, many cells showed punctate fluorescence condensation, and many such dots were frequently aligned just below the plane of the plasma membrane (Fig. 7, top, hatched  arrowheads) , reminiscent of the translocation of the fluorescent receptor B 1 R-YFP in response to Lys-des-Arg 9 -BK (Sabourin et al., 2002) . The differences between these proportions remained large and significant when the concentration of the fluorescent agents was changed to 50 nM, the agonist form consistently showing less membrane continuity (Fig. 7,  bottom; data not shown). In confocal sections (Fig. 7) , control experiments showed that some cell-associated fluorescence derives from a contribution of the cell autofluorescence at the employed settings and possibly from a minor receptor-independent uptake of the fluorescent peptides.
To investigate the identity of condensed structures that contain B-10378-associated fluorescence, a red-emitting fluorescent caveolin-1 conjugate was cotransfected with the rabbit B 1 receptor in HEK 293a cells (Fig. 8) . The red signal was observed both as particles close to the plasma membrane and in intracellular granules in control cells. The antagonist of comparable affinity at the rabbit B 1 receptor, B-10376 (20 nM), labeled the cell membranes in a rather smooth manner in additional confocal sections, whereas the green labeling associated with the agonist B-10378 often colocalized with that of caveolin-1 in coarse granules close to the plasma membrane in other cells (arrowheads in Fig. 8 point to examples of the described structures). It is also possible that agonist stimulation with B-10378 translocated a part of the caveolin-1 cytosolic granular signal close to the plasma membrane (data not shown).
Cytofluorometry. HEK 293a cell staining with B-10376 did not produce a level of cell-associated green fluorescence different from that of autofluorescence (Fig. 9, A and B) . However, approximately half of the cells that were submitted to transfection with a vector coding for the rabbit B 1 receptor exhibited intense fluorescence in the presence of B-10376 (Fig. 9D ). This distribution was acutely reversed to the level of autofluorescence if labeling was done in the presence of the nonpeptide antagonist, compound 11 (1 M; Fig. 9E ). As a physiological extension of the study, blockade of protein synthesis with anisomycin, present for the last 2 or 4 h of culture before staining with B-10376, reduced both the proportion of intensely fluorescent cells and the median intensity of their staining (Fig. 9, G and F, respectively) . This supports the previous suggestion that cell surface B 1 receptors are shortlived if their replacement by de novo synthesis is blocked (Fortin et al., 2003) .
The expression of the B 1 receptors in smooth muscle cells and some functional responses dependent on this receptor have been studied previously in smooth muscle cells derived from the human umbilical artery (Fig. 3) (Morissette et al., 2006; Moreau et al., 2007) . The green fluorescence of interleukin-1␤-pretreated cells incubated with the antagonist B-10376 (100 nM) was consistently higher than autofluorescence ( Fig. 10 ; P Ͻ 0.05, paired Student's t test) but overlapped with it in this system, where the receptor B max may represent ϳ1% of that of recombinant B 1 R-FLAG expressed in HEK 293a cells (Moreau et al., 2007; Morissette et al., 2008) . The nonpeptide antagonist compound 11 introduced in the presence of B-10376 during the staining procedure reduced the intensity of the fluorescent cell labeling in cytokine-treated cells, consistent with the labeling of the endogenous B 1 receptors.
Discussion
The objective of the present work was to evaluate the possibility of conjugating kinin B 1 receptor peptide ligands with a fluorophore to produce exploitable fluorescent probes. The known structure-activity relationships for peptide agonists and antagonists of this receptor have been considered before opting for N-terminal extension of the optimal agonist Lys-des-Arg 9 -BK and of the high-affinity antagonist B-9958 (see Introduction; Table 1 ). The resulting peptides have kept the pharmacological identities of the parent peptides in functional tests based on naturally expressed rabbit or human B 1 receptors. B-10378 was a full agonist, whereas B-10372 and jpet.aspetjournals.org B-10376 retain the surmountable antagonist properties of B-9958 in the rabbit aorta contractility assay; calcium transient results in human smooth muscle cells are compatible with this classification. However, the 5(6)-carboxyfluorescein N-terminal extension has produced a significant loss of affinity that differs for the antagonists and the agonist (more detrimental for the latter) and that is larger at the human than the rabbit B 1 receptor. This loss of affinity was present whether or not the ε-aminocaproyl "spacer" was introduced between the fluorophore and the peptide in the antagonist version (B-10372 and B-10376 exhibit very similar pharmacologic properties at both the rabbit and human B 1 receptors). It is clear that the affinities, measured as binding competition K i values at each receptor form (Table 2) , predict the lowest concentrations that may be used in microscopic cell labeling (Fig. 6) . The loss of affinity and the limited efficiency and rapid fading of the chosen fluorophore under continuous excitation show that there is room for improvement in the design of fluorescent B 1 receptor probes.
A practical problem in the development of a fluorescent receptor probe for use in live cells is nonspecific uptake. For instance, the uptake of cationic peptides labeled at their N termini with 5(6)-carboxyfluorescein can follow various pathways but essentially concerns large (micromolar) concentrations; clathrin-mediated endocytosis and caveolae/lipid raftmediated endocytosis were documented (Duchardt et al., 2007) . Furthermore, B-10378, largely made from natural amino acids, can potentially be degraded and the N-terminal fragments subjected to a form of uptake. Despite all limitations, various controls (experiments in the absence of receptors, competition with a nonpeptide antagonist not structurally related to ligands) support that most of the cell labeling that we have observed at the rabbit and human B 1 receptors is specific at the nanomolar concentration range exploited, and original applications remained possible because the affinities of the probes were acceptable. Two types of applications were pursued: the differential effect of agonist and antagonist ligands on plasma membrane location of the B 1 receptors and the identification of a population of these receptors using cytofluorometry. The agonist version seemed to reproduce the lateral translocation of the receptor that has been observed with a fluorescent B 1 receptor construction in confocal microscopy (Sabourin et al., 2002) , with punctate staining that was often just below the plane of the plasma membrane and possibly localized to caveolae (Fig. 7) , because noncaveolar lipid rafts are not likely to be resolved in confocal optical microscopy (for examples, see Fortin et al., 2005b) . The staining observed with the antagonist B-10376 was smoother, given the uneven receptor expression obtained with transient receptor expression. The demonstration is particularly convincing at the rabbit B 1 receptor because the affinities of the agonist and antagonist fluorescent peptides are similar in absolute K i values (Table 2 ), but the data at the human B 1 receptors are also consistent with the effect of the agonist on receptor distribution because this applied over a range of fluorescent ligand concentrations. The use of fluorescent agonist and antagonist ligands is complementary to that of the previously reported fluorescent receptor B 1 R-YFP because the ligands are more likely to influence only cell surface receptor without interference from possible intracellular pools of receptors. This approach, based on live and intact cells, essentially confirmed the previous suggestion of the unique form of agonist-induced adaptation for the nonphosphorylated B 1 receptor (Ostrom, 2002; Sabourin et al., 2002) : caveolar translocation without important internalization. Red-emitting caveolin-1 often colocalized with the agonist B-10378, in support of this hypothesis (Fig. 8) . This approach has limitations because the overexpression of caveolin-1-ChFP may enrich the density of caveolae in HEK 293a cells, and these caveolae may extend as convoluted tubes that occasionally extend far from the plasma membrane, explaining occasional colocalization in cytosolic granules (Fig. 8) .
The second type of application was the detection of the cell surface B 1 receptor population using cytofluorometry. The antagonist B-10376 evidenced the variable density of B 1 receptors at the surface of HEK 293a cells, from a null to an intense level, directly showing transfection efficiency. As seen with other cellular systems, the cell surface population of B 1 receptors is the result of the combined de novo synthesis and ligand-independent degradation (Fortin et al., 2003) . The antagonist B-10376 was also exploited to detect the endogenous low levels of B 1 receptors in cultured human smooth muscle cells known to express these receptors. It remains to be seen whether B 1 receptor determination in leukocytes (e.g., peripheral mononuclear cells in patients with multiple sclerosis, Prat et al., 2005) has any clinically useful application. Further possible uses of a fluorescent ligand could be to detect the receptors in frozen tissue sections and to sort living cells that express the corresponding receptors; for instance, to select stable transfectant cells from a population that expresses a nonfluorescent receptor construction. A fluorophore has been introduced in B 1 receptor agonist or antagonist peptides at the expense of a certain loss of affinity, but the resulting agents allowed original applications (imaging in live cells that support agonist-induced caveolar translocation, cytofluorometry). 
